This page shows the latest Tecentriq news and features for those working in and with pharma, biotech and healthcare.
Roche’s Tecentriq is a cancer immunotherapy that has the potential to be used in combination with other immunotherapies, targeted medicines and various chemotherapies across a broad range of cancers. ... In June this year, Tecentriq was approved by the
Subcutaneously administering Tecentriq reduced the time needed for treatment compared to standard IV infusion. ... The investigational subcutaneous formulation combines Tecentriq with Halozyme Therapeutics’ Enhanze drug delivery technology.
Tecentriq has now become the first cancer immunotherapy approved in Europe for the treatment of certain types of early-stage NSCLC. ... The safety data taken from the study were consistent with Tecentriq’s known safety profile, while no new safety
Following approval from the Medicines and Healthcare products Regulatory Agency (MHRA), Roche's atezolizumab (Tecentriq) can be used to treat non-small cell lung cancer (NSCLC).
survival (PFS) over Tecentriq alone after an average of 10.9 months follow-up. ... plus Tecentriq in early and metastatic disease in both lung and oesophageal cancers.
Roche had to withdraw its US accelerated approval for its immuno-oncology drug Tecentriq (atezolizumab) in combination with chemotherapy earlier this year when a post-marketing study failed to show benefit.
More from news
Approximately 72 fully matching, plus 90 partially matching documents found.
2019. The only drug that has any realistic chance of challenging Keytruda in NSCLC is Roche’s Tecentriq. ... The Tecentriq chemo trial, IMpower132, is the most important head-to-head with Keytruda (in non-squamous NSCLC).
The therapy area is dominated by Merck’s Keytruda, BMS’ Opdivo and Roche’s Tecentriq, but Pfizer is hoping that combinations such as its own Inlyta and Bavencio can help it
It’s not all been plain sailing, with BMS’ Opdivo (nivolumab) and Roche’s Tecentriq not doing as well as hoped in frontline NSCLC, revealing there are differences between checkpoint inhibitors – ... The drugmaker thinks Avastin may enhance
Tecentriq (for the treatment of urothelial carcinoma, only approved in the US), and Venclexta (for the treatment of chronic lymphocytic leukaemia, approved in the EU and US).
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
WE’RE ON A MISSION
To transform lives through communication that changes behaviour and improves health outcomes....